MDxHealth (MXDHF) Stock Price, News & Analysis

Company Overview

MDxHealth is a molecular diagnostics company that develops and commercializes laboratory tests designed to support personalized cancer care and urological disease management. Its tests analyze genetic and molecular information from tissue, urine, and other biological samples to help physicians assess disease risk, improve diagnosis, and guide treatment decisions.

The company’s urology portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy, and SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer before biopsy. MDxHealth also offers ResolveMDx, a molecular test designed to identify pathogens associated with urinary tract infections and provide information that can support antibiotic selection. Its portfolio has also included genomic testing for prostate cancer prognosis and treatment planning.

MDxHealth was founded in Belgium in 2003 and has expanded its operations in the United States and Europe. The company is headquartered in Irvine, California, and serves physicians, hospitals, laboratories, and patients through its commercial laboratory and diagnostic services infrastructure. Its products are primarily focused on urology, with an emphasis on prostate cancer detection, risk stratification, and treatment decision-making.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 300 shs
• Average Volume: 1,000 shs
• Market Capitalization: $3.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Company Calendar

• Today: 10/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MXDHF
• Previous Symbol: NASDAQ:MXDHF
• CIK: N/A
• Web: www.mdxhealth.com
• Phone: (324) 257-7071
• Fax: 32042597875
• Employees: 252
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.45
• Current Ratio: 1.25
• Quick Ratio: 1.19

Sales & Book Value

• Annual Sales: $37.05 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.60 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 15,597,000
• Free Float: 15,332,000
• Market Cap: $3.90 million
• Optionable: Not Optionable
• Beta: 1.46